Can Fascaplysins Be Considered Analogs of Indolo[2,3-<i>a</i>]pyrrolo[3,4-<i>c</i>]carbazoles? Comparison of Biosynthesis, Biological Activity and Therapeutic Potential
2025
Maxim E. Zhidkov | Aleksandr M. Popov | Olga A. Soldatkina | Oleg A. Tryapkin | Lyubov N. Kharchenko
For the first time, a comparative analysis has been conducted to elucidate the biosynthesis of three families of natural products—staurosporines/rebeccamycins, cladoniamides, and fascaplysins. Based on the available data, a well-founded hypothesis was formed that these metabolites arise through a shared biosynthetic pathway. A comparative evaluation of biological activity profiles and molecular mechanisms of action of the major representatives of these alkaloid families and their derivatives shows that, despite an apparent similarity between the activity spectra of indolo[2,3-<i>a</i>]pyrrolo[3,4-<i>c</i>]carbazoles and fascaplysins, they operate through different mechanisms. The biological effects of fascaplysin are driven primarily by the induction of metabolic stress rather than by the inhibition of DNA topoisomerase I or of a broad-spectrum protein kinases. The successful optimization of natural indolo[2,3-<i>a</i>]pyrrolo[3,4-<i>c</i>]carbazoles—compounds with initially poorer pharmacokinetic properties than those of fascaplysin—to drug-like candidates underscores the substantial pharmaceutical potential of the fascaplysin scaffold. Several existing fascaplysin derivatives, after the improvement of their pharmacokinetic characteristics, may serve as promising leads for the development of a new class of antibiotics.
Afficher plus [+] Moins [-]Mots clés AGROVOC
Informations bibliographiques
Cette notice bibliographique a été fournie par Directory of Open Access Journals
Découvrez la collection de ce fournisseur de données dans AGRIS